Abstract CT132: First in human trial of BAY2965501, a selective inhibitor of intra-cellular T cell checkpoint diacylglycerol kinase zeta (DGKζ), as monotherapy and combination with anti-PD-1
Year: 2026
Type: conference-abstract
Source: Cancer Research
Authors: Ruth Plummer, Anna Minchom, Ramon Yarza, Hans Prenen, Mark R Middleton, Kyriakos Papadopoulos, Hye Ryun Kim, Tatiana Hernandez, Ignacio Melero, Ignacio Ortego Zabalza, Enriqueta Felip, Seung Tae Kim, Toshihiko Doi, Keun-Wook Lee, Sarah Taylor, Debashsis Sarker, Yulin Li, Maribel Salas, Jochen Schulze, Stephen Ducray, Huijuan Su, Yuqing Xiao, Alexandre Desjonqueres, Andrea Frohwann, Bart Ploeger, Konstantin Lang, Stephanie Lapointe, Kristen Armstrong, Alison Edgar, Christoph Mancao, David A. Schaer, Stefanie Reif, Leila Khoja, Jason Henry
Institutions: Newcastle University, Royal Marsden Hospital, Antwerp University Hospital, University of Oxford, South Texas Accelerated Research Therapeutics, Yonsei University, Severance Hospital, Yonsei University Health System, Clinica Universidad de Navarra, Universidad de Navarra, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Samsung Medical Center, Seoul National University Bundang Hospital, King's College London, Bayer (United States), Bayer (Switzerland), Bayer (Germany), Bayer (Canada), HealthONE
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7154704442
Cites:
Cited by:
Related to: